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Other names: TIG1 
Location: 3q25.32 
Local order: Telomeric to MFSD1 and centromeric to 
GFM1 and LXN 
Note: RARRES1 (retinoic acid receptor responder 1) is 
also known as TIG1 (Tazarotene-induced gene 1). The 
gene was initially identified as a target gene that w s 
induced by the synthetic retinoid tazarotene (AGN 
190168) in human skin raft cultures. It is upregulated 
by retinoic acid receptor-specific but not by retinoid X  
 
receptor-specific retinoids. 
As noted in the early published articles, the authors 
mentioned that RARRES1 (TIG1) is located at 3p12-
13. The location was subsequently confirmed to be 
incorrect. UCSC Genome Browser on Human Mar. 
2006 Assembly shows that the RARRES1 should be 
located between 3q25.32 and 3q25.33. 
DNA/RNA 
Description 




Two transcript variants (isoform 1: NM_206963.1 and isoform 2: NM_002888.2) are shown. Black boxes represent the exons of 
RARRES1. CpG: location of CpG island. 
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Two alternatively spliced transcripts were identified 
(isoform 1 and isoform 2). Exons 1 to 4 are common to 
both isoforms. Exon 5 and 6 are present in isoform 1 
(NM_206963.1) only. The cDNA of isoform 1 is 1545 
bp while isoform 2 is 886 bp. 
Pseudogene 
No known pseudogenes. 
Protein 
Description 
Called Retinoic acid receptor responder protein 1 
(synonyms: Tazarotene-induced gene 1 protein/RAR-
responsive protein TIG1); Two isoform, isoform 1 
(NP_996846) and isoform 2 (NP_002879), produced 
by alternative splicing were reported. Isoforms 1 and 2 
contain 294 and 228 amino acids respectively. 
Molecular weight of Isoform 1 is 33258 Da. The two 
isoforms show difference in the 3'end-region. 
RARRES1 is predicted to be a transmembrane protein 
with a small N-terminal intracellular regions, a single 
membrane-spanning hydrophobic region, and a large 
C-terminal extracellular region containing a 
glycosylation signal. 
Expression 
High level of RARRES1 transcripts was detected in 
multiple tissues including prostate, heart, lung, liver, 
colon and small intestine. Expression of RARRES1 
protein was demonstrated in colorectal tissues. 
Localisation 
Based on the predicted amino acid sequence, 
RARRES1 is suspected to be a transmembrane protein. 
However, immunohistochemical analysis showed that 
RARRES1 protein localizes at the supranuclear regions 
of colorectal adenocarcinoma, adenoma and adjacent 
normal epithelial cells. The precise localization of 
RARRES1 protein needed to be further investigated. 
Function 
RARRES1 was suggested to be a tumor suppressor of a 
variety of human cancers. Inactivation of RARRES1 is 
involved in the malignant progression of prostate 
cancer. Restoration of RARRES1 expression in 
malignant prostate cell lines led to a decrease of 
invasiveness and tumorigenicity in nude mice. It is 
speculated that RARRES1 may function as a cell 
adhesion molecule. Since the protein shows sequence 
similarity to Latexin, the only known mammalian 
carboxypeptidase inhibitor, RARRES1 may also have 
protease inhibitor activity and inhibit the degradation of 
extracellular matrix. 
Homology 
RARRES1 belongs to the proteinase inhibitor I47 
(latexin) family, its c-terminal region shows 30% 
sequence similarity with Latexin. 
Mutations 
Note: No germline or somatic mutation associated with 
disease is reported. 
Implicated in 
A variety of human cancers 
Note: The association of RARRES1 with human 
cancer was first revealed by the subtractive differential 
gene display analysis of benign and malignant prostate 
cell lines. The gene was expressed in benign prostate 
cell lines and not in malignant ones. It is now 
considered as a putative tumor suppressor gene in a 
variety of human cancers although its function remains 
unclear. Its expression is commonly suppressed in 
prostate carcinoma, lung cancer, nasopharyngeal 
carcinoma, and leukemia by promoter 
hypermethylation. Restoring RARRES1 expression in 
prostate cancer cells resulted in decrease of in vitro 
invasiveness and in vivo tumorigenicity. RARRES1 






Atlas Genet Cytogenet Oncol Haematol. 2007;11(2)  123 
also implicated in therapeutic effects of retinoic acid in 
psoriasis. 
Disease 
Prostate carcinoma, nasopharyngeal carcinoma, head 
and neck cancer, lung cancer, gastric carcinoma, 
colorectal adenocarcinoma, endometrial cancer, breast 
cancer, acute myeloid leukemia, Chronic myeloid 
leukemia. 
Prognosis 
Down-regulation of RARRES1 is significantly related 
with the late stage colorectal adenocarcinoma (Dukes's 
stage D). However, no difference in survival was found 
comparing patient with negative, weak and strong 
RARRES1 expression in tumors. 
Cytogenetics 
No translocations and amplifications of this gene have 
been reported. 
Hybrid/Mutated Gene 
No hybrid gene involving RARRES1 has been 
described. 
Breakpoints 
Note: No breakpoints involving this gene have been 
described. 
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